🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)

Recruitingn/aAges 14 Years - anyAllRuijin Hospital
NCT06534463 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study aims to evaluate real-world treatment modalities and their corresponding effectiveness and safety in Chinese patients with marginal zone lymphoma, while also exploratively analyzing patient characteristics and health-related quality of life.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Be diagnosed as MZL * Meet the treatment indications for MZL Exclusion Criteria: * Any reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study.
💊

What it tests

  • All treatment regimen selections and usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.
📍

Where

1 site
Shanghai Ruijin Hospital
Shanghai, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy